Research Updates Archives • Page 8 of 8 • FRAXA Research Foundation

Fragile X Treatment Strategy Emerges from FRAXA Research: IGF-1

July 30, 2013

Neuren’s Trofinetide, part of a promising IGF-1 drug class, showed standout results in Fragile X mice—outperforming Rett syndrome models.

Lovastatin Discovery in Fragile X Mice Leads FRAXA to Fund Clinical Trials

June 11, 2013

FRAXA honored Dr. Emily Osterweil for discovering that lovastatin can correct key Fragile X abnormalities. Her findings were published in Neuron.

Phase 2b Clinical Trial of Arbaclofen in Autism Has Disappointing Results

May 14, 2013

The Phase 2b arbaclofen trial in autism didn’t improve social withdrawal, but did show progress on the Clinical Global Impression of Severity scale.

Clinical Trials FAQ ← Frequently Asked Questions

January 11, 2013

Wondering which Fragile X trial is right? Eligibility varies, so most families qualify for just one. Talk with your closest clinic to find the best fit.

FRAXA Progress and Future Plans

November 27, 2012

Huge momentum in Fragile X research: major results released, widespread media attention, and Phase III trials moving toward possible treatments.

What Works, and What Doesn’t

September 7, 2012

Early on, no one knew which path would work. Now the results are clear, and they’re directing FRAXA toward the next major Fragile X treatment breakthrough.

Compound that Inhibits mGluR5 Corrects Signs of Fragile X in Adult Mice

April 13, 2012

A Roche and MIT study published in Neuron finds that an mGlu5 inhibitor, CTEP, can reverse many Fragile X symptoms in adult mice.

FRAXA Announces 2012 Fragile X Research Awards

April 3, 2012

$1.13 million in FRAXA funding in 2012 supported new Fragile X research projects and renewals, advancing work toward better treatments.

Fragile X Research Grants and Fellowships Funded 2011

April 7, 2011

Over $1 million in FRAXA funding in 2011 supported leading Fragile X research projects focused on developing effective treatments and future cures.

FRAXA 2010 Research Awards Funded

July 11, 2010

Over $1.5 million in FRAXA funding supported Fragile X research and fellowships in 2010, empowering scientists to pursue breakthrough treatments.

Results of First Fenobam Trial in Adults with Fragile X Published

July 1, 2009

Fenobam showed positive results in a Phase IIa Fragile X trial. FRAXA supplied data that helped the drug earn Orphan status and move into clinical testing.